Eli Lilly and Johnson & Johnson both touted data Monday for their IL-23 inhibitors in Crohn’s disease, with Lilly also sharing long-term data in ulcerative colitis.
In the Phase 3 GRAVITI study, J&J's subcutaneous Tremfya ...
↧